Crinetics Pharmaceuticals, Inc. (CRNX)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
83.67 USD
+0.09
(0.108%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:44 a.m. EDT
The market has priced in a transformative acquisition, sending shares to their 52-week high. While revenue growth is robust at nearly 30%, the underlying business remains unprofitable with negative free cash flow and return on equity. The options chain reveals a heavy concentration of contracts at the $85 strike, suggesting traders view that level as a hard ceiling. The statistical forecast offers no directional guidance, highlighting the binary nature of the deal. Investors are betting on the merger's completion rather than organic growth, creating a high-risk, high-reward environment where the deal terms dictate the ceiling. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.126842 |
| AutoARIMA | 0.126844 |
| MSTL | 0.132066 |
| AutoTheta | 0.134765 |
| MSTL_74 | 0.151026 |
| MSTL_97 | 0.154744 |
| MSTL_74_97 | 0.161600 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 17% |
| H-stat | 63.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 7.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.737 |
| Revenue per Share | 0.187 |
| Market Cap | 8,855,652,352 |
| Forward P/E | -20.56 |
| Beta | 0.23 |
| Website | https://www.crinetics.com |
As of July 11, 2026, 5:44 a.m. EDT: Speculators are positioning for a range-bound outcome near the current price, with a significant open interest wall at the $85 strike for calls, acting as a psychological barrier. Put buyers are concentrated at $75 and $80, indicating a desire for downside protection if the deal faces hurdles. Implied volatility is compressed at the money, suggesting the market expects the price to remain stable around the acquisition premium.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5311933 |
| Address1 | 6,055 Lusk Boulevard |
| All Time High | 83.76 |
| All Time Low | 10.63 |
| Ask | 107.09 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.7 - Hold |
| Average Daily Volume10 Day | 13,164,320 |
| Average Daily Volume3 Month | 3,137,718 |
| Average Volume | 3,137,718 |
| Average Volume10Days | 13,164,320 |
| Beta | 0.233 |
| Bid | 60.23 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 12.16 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 83.67 |
| Current Ratio | 18.603 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 83.69 |
| Day Low | 83.59 |
| Debt To Equity | 3.737 |
| Display Name | Crinetics Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,873,600 |
| Earnings Call Timestamp Start | 1,785,873,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | -541,617,024 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.993 |
| Enterprise To Revenue | 419.433 |
| Enterprise Value | 7,578,731,008 |
| Eps Current Year | -4.62077 |
| Eps Forward | -4.06917 |
| Eps Trailing Twelve Months | -5.15 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 40.4566 |
| Fifty Day Average Change | 43.213398 |
| Fifty Day Average Change Percent | 1.068142 |
| Fifty Two Week Change Percent | 153.11932 |
| Fifty Two Week High | 83.76 |
| Fifty Two Week High Change | -0.09000397 |
| Fifty Two Week High Change Percent | -0.0010745459 |
| Fifty Two Week Low | 25.83 |
| Fifty Two Week Low Change | 57.839996 |
| Fifty Two Week Low Change Percent | 2.2392566 |
| Fifty Two Week Range | 25.83 - 83.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,531,920,600,000 |
| Float Shares | 95,546,753 |
| Forward Eps | -4.06917 |
| Forward P E | -20.561932 |
| Free Cashflow | -242,135,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 594 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -339,105,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01594 |
| Held Percent Institutions | 1.1981 |
| Implied Shares Outstanding | 105,840,233 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
| Long Name | Crinetics Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 8,855,652,352 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_280584191 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -496,388,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,855,652,295 |
| Number Of Analyst Opinions | 10 |
| Open | 83.67 |
| Operating Cashflow | -414,172,992 |
| Operating Margins | -13.07788 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 450 6464 |
| Pre Market Change | -0.26999664 |
| Pre Market Change Percent | -0.3226923 |
| Pre Market Price | 83.4 |
| Pre Market Time | 1,784,016,021 |
| Previous Close | 83.58 |
| Price Eps Current Year | -18.107372 |
| Price Hint | 2 |
| Price To Book | 6.8807564 |
| Price To Sales Trailing12 Months | 490.10196 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.245 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.71429 |
| Region | US |
| Regular Market Change | 0.0899963 |
| Regular Market Change Percent | 0.107677 |
| Regular Market Day High | 83.69 |
| Regular Market Day Low | 83.59 |
| Regular Market Day Range | 83.59 - 83.69 |
| Regular Market Open | 83.67 |
| Regular Market Previous Close | 83.58 |
| Regular Market Price | 83.67 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 6,040,828 |
| Return On Assets | -0.24693 |
| Return On Equity | -0.39168 |
| Revenue Growth | 28.734 |
| Revenue Per Share | 0.187 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 105,840,233 |
| Shares Percent Shares Out | 0.1313 |
| Shares Short | 13,845,220 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,639,107 |
| Short Name | Crinetics Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1538 |
| Short Ratio | 11.14 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRNX |
| Target High Price | 90.0 |
| Target Low Price | 55.0 |
| Target Mean Price | 82.5 |
| Target Median Price | 85.0 |
| Total Cash | 1,291,305,984 |
| Total Cash Per Share | 12.247 |
| Total Debt | 47,855,000 |
| Total Revenue | 18,069,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 42.868275 |
| Two Hundred Day Average Change | 40.801723 |
| Two Hundred Day Average Change Percent | 0.951793 |
| Type Disp | Equity |
| Volume | 6,040,828 |
| Website | https://www.crinetics.com |
| Zip | 92,121 |